Faculty

Back to Index
Welmoed Kirsten van Deen, MD
Assistant Professor of Research Medicine
Medicine
GNH 1937 Hospital Place Off Campus Los Angeles

Overview

Dr. van Deen's major areas of research interest are value-based healthcare implementation and outcome and utilization measurement. She is currently a member of the International Consortium for Health Outcomes Measurement (ICHOM) IBD Standard Set Working Group.

Dr. van Deen earned her medical degree from Leiden University Medical Center. She then returned to complete her PhD in Medicine a few years later.

Awards

Leiden University, The Netherlands: LUSTRA Travel Scholarship, 2011

American Gastroenterological Association: Digestive Disease Week Poster of Distinction Award, 2015

Publications

Van Deen WK, van der Meulen-de Jong AE, Parekh NK, Kane E, Zand A, DiNicola CA, Hall L, Inserra EK, Choi JM, Ha CY, Esrailian E, van Oijen MG, Hommes DW. Development and Validation of an Inflammatory Bowel Diseases Monitoring Index for Use With Mobile Health Technologies. Clin Gastroenterol Hepatol. 2016 Dec; 14(12):1742-1750. e7. View in: PubMed

Polytarchou C, Hommes DW, Palumbo T, Hatziapostolou M, Koutsioumpa M, Koukos G, van der Meulen-de Jong AE, Oikonomopoulos A, van Deen WK, Vorvis C, Serebrennikova OB, Birli E, Choi J, Chang L, Anton PA, Tsichlis PN, Pothoulakis C, Verspaget HW, Iliopoulos D. MicroRNA214 Is Associated With Progression of Ulcerative Colitis, and Inhibition Reduces Development of Colitis and Colitis-Associated Cancer in Mice. Gastroenterology. 2015 Oct; 149(4):981-992. e11. View in: PubMed

Polytarchou C, Hommes DW, Palumbo T, Hatziapostolou M, Koutsioumpa M, Koukos G, van der Meulen-de Jong AE, Oikonomopoulos A, van Deen WK, Vorvis C, Serebrennikova OB, Birli E, Choi J, Chang L, Anton PA, Tsichlis PN, Pothoulakis C, Verspaget HW, Iliopoulos D. MicroRNA214 Is Associated With Progression of Ulcerative Colitis, and Inhibition Reduces Development of Colitis and Colitis-Associated Cancer in Mice. Gastroenterology. 2015 Oct; 149(4):981-992. e11. View in: PubMed

Zand A, van Deen WK, Inserra EK, Hall L, Kane E, Centeno A, Choi JM, Ha CY, Esrailian E, D'Haens GR, Hommes DW. Presenteeism in Inflammatory Bowel Diseases: A Hidden Problem with Significant Economic Impact. Inflamm Bowel Dis. 2015 Jul; 21(7):1623-30. View in: PubMed

Zand A, van Deen WK, Inserra EK, Hall L, Kane E, Centeno A, Choi JM, Ha CY, Esrailian E, D'Haens GR, Hommes DW. Presenteeism in Inflammatory Bowel Diseases: A Hidden Problem with Significant Economic Impact. Inflamm Bowel Dis. 2015 Jul; 21(7):1623-30. View in: PubMed

van Deen WK, Esrailian E, Hommes DW. Value-based health care for inflammatory bowel diseases. J Crohns Colitis. 2015 May; 9(5):421-7. View in: PubMed

van Deen WK, Esrailian E, Hommes DW. Value-based health care for inflammatory bowel diseases. J Crohns Colitis. 2015 May; 9(5):421-7. View in: PubMed

Oikonomopoulos A, van Deen WK, Manansala AR, Lacey PN, Tomakili TA, Ziman A, Hommes DW. Optimization of human mesenchymal stem cell manufacturing: the effects of animal/xeno-free media. Sci Rep. 2015; 5:16570. View in: PubMed

van Deen WK, van Oijen MG, Myers KD, Centeno A, Howard W, Choi JM, Roth BE, McLaughlin EM, Hollander D, Wong-Swanson B, Sack J, Ong MK, Ha CY, Esrailian E, Hommes DW. A nationwide 2010-2012 analysis of U. S. health care utilization in inflammatory bowel diseases. Inflamm Bowel Dis. 2014 Oct; 20(10):1747-53. View in: PubMed

Oikonomopoulos A, van Deen WK, Hommes DW. Anti-TNF antibodies in inflammatory bowel disease: do we finally know how it works? Curr Drug Targets. 2013 Nov; 14(12):1421-32. View in: PubMed

Oikonomopoulos A, van Deen WK, Hommes DW. Anti-TNF antibodies in inflammatory bowel disease: do we finally know how it works? Curr Drug Targets. 2013 Nov; 14(12):1421-32. View in: PubMed

van Deen WK, Hommes DW. IBD: Antibodies to anti-TNF therapy--consequences for IBD management. Nat Rev Gastroenterol Hepatol. 2013 Aug; 10(8):446-8. View in: PubMed

van Deen WK, Hommes DW. IBD: Antibodies to anti-TNF therapy--consequences for IBD management. Nat Rev Gastroenterol Hepatol. 2013 Aug; 10(8):446-8. View in: PubMed

van Deen WK, Oikonomopoulos A, Hommes DW. Stem cell therapy in inflammatory bowel disease: which, when and how? Curr Opin Gastroenterol. 2013 Jul; 29(4):384-90. View in: PubMed

van Deen WK, Oikonomopoulos A, Hommes DW. Stem cell therapy in inflammatory bowel disease: which, when and how? Curr Opin Gastroenterol. 2013 Jul; 29(4):384-90. View in: PubMed

van Deen WK, Hommes DW. Mucosal schwann cell hamartoma in ulcerative colitis: diagnosis and clinical relevance. Gastroenterol Hepatol (N Y). 2013 Mar; 9(3):185-6. View in: PubMed

van Deen WK, Hommes DW. Mucosal schwann cell hamartoma in ulcerative colitis: diagnosis and clinical relevance. Gastroenterol Hepatol (N Y). 2013 Mar; 9(3):185-6. View in: PubMed

Molendijk I, Duijvestein M, van der Meulen-de Jong AE, van Deen WK, Swets M, Hommes DW, Verspaget HW. Immunomodulatory effects of mesenchymal stromal cells in Crohn's disease. J Allergy (Cairo). 2012; 2012:187408. View in: PubMed

Molendijk I, Duijvestein M, van der Meulen-de Jong AE, van Deen WK, Swets M, Hommes DW, Verspaget HW. Immunomodulatory effects of mesenchymal stromal cells in Crohn's disease. J Allergy (Cairo). 2012; 2012:187408. View in: PubMed

Powered bySC CTSI